This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The US Drug Enforcement Administration (DEA) has once again pledged to take action to better facilitate clinical cannabis research. In 2016, the DEA similarly announced the adoption of new rules to expand to supply of research-grade cannabis, but failed to take any further action.
Moreover, the ball is in the Drug Enforcement Agency’s (DEA) court. The FDA can make recommendations to the DEA about substances subjected to scheduling under the CSA, but the DEA is the entity with the power to reschedule CBD. In the recent case Hemp Industries Associations v.
Aurum Labs ( [link] ) is now certified by the Colorado Department of Public Health and Environment (CDPHE) to conduct hemp compliance testing for manufactured industrial hemp products and is in the final stages of Drug Enforcement Agency (DEA) registration.
As a Marine Corps federal prosecutor, DEA Drug Task Force Commander and state narcotics prosecutor, Charles spent many years engaged in the War on Drugs. A Former DEA Prosecutor’s Journey into the Global Cannabis Industry. Charles Feldmann, Esq. CannaTech alumnus sponsor and cannabis legal expert. ” – Famous Russian proverb.
According to the Daily, the testing delay comes after farmers and states alike complained there wouldn’t be enough DEA labs to handle demand. We now better understand how the limited number of DEA-registered labs will hinder testing and better understand the associated costs with disposing of product that contains over 0.3%
In recent months, the DEA has issued a select number of licenses to several groups in the US to allow for the cultivation of Cannabis for scientific research purposes. Under the federal licensing regime, BRC is only allowed to source genetics and starting material from DEA-compliant or federally legal sources.
(OTC: CURR), a vertically integrated drug delivery and product development company, announced today that it has signed a partnership agreement with Biopharmaceutical Research Company , (BRC), an active Drug Enforcement Administration (DEA) license holder, to produce federally-compliant cannabis-based medical products.
MONTEREY, CA – Biopharmaceutical Research Company (BRC), an active Drug Enforcement Administration (DEA) license holder, and CURE Pharmaceutical Holding Corp. CURE currently produces multiple commercial CBD oral film products in compliance with the 2018 U.S.Farm Bill and European regulations.
Another potential headache for farmers is that analytical laboratories must be registered with the DEA in order to perform compliance testing. No existing cannabis labs are registered with the DEA because they handle a schedule 1 substance, which violates federal law. and seize all the testing samples. THC threshold.
Charles Feldmann, a former DEA Drug Task Force Commander and former state’s narcotics prosecutor, will be sharing his insight and expertise on the other side of the cannabis constitutional law. Mr. Feldmann’s talk is titled, “The United States Federal Government and the Cannabis Industry.
Compliance is critical to reducing liability risks and expanding market opportunities, and unfortunately, most laboratories do not offer comprehensive testing,” said Roger Brown, president of ACS Laboratory. Specifically, they invested in highly sensitive instrumentations that could quantify the lowest action limits. “We
We would love to have you tune in to the discussion as our expert panelists discuss the following topics: Navigating regulatory compliance; Where to start and how. FDA, USDA, DEA basics. Future projections for compliance. Useful resources. Appropriate vs. inappropriate health claims.
Most of us in the hemp industry are well-aware of the major issues in the interim rules: 15-day pre-harvest testing requirements, total THC, DEA laboratories, and crop insurance to name a few. 15-day preharvest testing by a DEA registered laboratory. WFRP coverage is often used for specialty and non-traditional crops. 3% Total THC.
Marijuana industry operators were left unfazed when Jeff Session’s marijuana enforcement memorandum was released in January and the Obama era “Cole Memo” was rescinded, which relaxed the use of federal resources to prosecute marijuana businesses in compliance with state law.
Starting today, US manufacturers and merchants can apply through LegitScript to certify CBD products and websites that are in compliance with USDA, FDA, FTC, and DEA regulations, as well as state-specific laws.
percent delta-9 tetrahydrocannabinol or opportunities for remediation or alternative uses; the feasibility of producer compliance with sampling timetables; the feasibility of producer compliance with reporting requirements; and. For the FDA, this seems to be based on the agencies continued hostility towards Hemp CBD.
Attorney Charles Feldmann—former DEA Task Force Commander himself—understands government policy and utilizes his background to help his clients in the marijuana industry achieve and maintain strict compliance with state and federal regulations.
The importation of the naturally derived psilocybin into California was completed after the Company’s supply partner Mycrodose Therapeutics was granted an import license from the United States Drug Enforcement Administration (DEA). “With their track-record of working with the U.S. . Drug Enforcement Administration.
Ultimately, while the 2018 Farm Bill clarified that hemp is not a controlled substance – and the Drug Enforcement Administration (“DEA”) has no authority over it – the legislation did not resolve lingering questions related to federal food and drug regulations which protect consumer safety, as overseen by the Food and Drug Administration (“FDA”).
Manufacturers are responsible for certifying records, including all product data, which includes, for example, information on formulation, labeling, and DEA Schedule. Product listing certification requires manufacturers to ensure, on an annual basis, that its directory listing is updated and accurate. CBD Class Action Litigation.
The Commission believes this “narrow timeframe” is an “unnecessary obstacle for compliance.” The interim hemp rules require that hemp be tested 15-days prior to harvest. ” Factors such as weather could require that growers harvest hemp earlier than expected, without knowing whether hemp material is compliant.
or less is within the distribution or range, then the sample will be considered to be hemp for the purpose of compliance with the requirements of State, Tribal, or USDA hemp plans. Labs that test cannabis for THC levels must be registered with the DEA. Because 0.3% Because 0.3% Interstate Transport. ” What is 7 U.S.C.
Laboratory must be DEA-registered. is within that range, then the sample will be considered to be hemp for purposes of compliance with the requirements of State, Tribal, or USDA hemp plans: For example, if a laboratory reports a result as 0.35% with a measurement of uncertainty of +/- 0.06, the distribution or range is 0.29% to 0.41%.
Many states are now scrambling to close legal loopholes in their drug laws to bring delta-8 into regulatory compliance. But my contacts at the American Herbal Products Association, as well as the DEA (Drug Enforcement Administration) and the American Western Hemp Professionals, and the U.S. But how long will that legal status last?
Federal law requires that taxpayers must report income from illegal sources – including cannabis sales (whether state sanctioned or not) – raising numerous tax compliance and design issues. The lawful cannabis industry faces numerous regulatory hurdles that makes even good-faith compliance with the law a challenge. Introduction.
The first crisis point initiated by the Rule is its requirement that Labs “ must be registered by the DEA to conduct chemical analysis of controlled substances (in accordance with 21 CFR 1301.13). ” The USDA helpfully indicates that it will post directions for obtaining a DEA registration. Will that disqualify Labs in those states?
Responding to industry requests for predictability and uniformity in testing, the regulation sets minimum standards for basic compliance with the requirement that hemp must be 0.3% DEA will continue to have a role in the hemp program. must be accomplished under DEA guidance. USDA also provides a required lab report format.
Portland, OR — The Oregon Liquor Control Commission’s compliance and enforcement team was instrumental in the dismantling of an illegal marijuana processing site by local, state and federal law enforcement last week in rural Lane County.
The first argument was that according to the DEA, Delta-8 remains a schedule I substance because its method of manufacture is “synthetically-derived.” Thompson Hine LLP is available to assist vapor businesses with their compliance needs. In other words, any contrary agency language is overridden by clear statutory text. 202.263.4128.
Depending on the allegations, companies must also stay attentive to federal criminal exposure if information is shared with the Drug Enforcement Agency (DEA). The best protective measure a company can take is to conduct its own internal investigation or, at a minimum, a compliance review. The Legal Gray Area of the Initial Grow.
Depending on the allegations, companies must also stay attentive to federal criminal exposure if information is shared with the Drug Enforcement Agency (DEA). The best protective measure a company can take is to conduct its own internal investigation or, at a minimum, a compliance review. The Legal Gray Area of the Initial Grow.
Depending on the allegations, companies must also stay attentive to federal criminal exposure if information is shared with the Drug Enforcement Agency (DEA). The best protective measure a company can take is to conduct its own internal investigation or, at a minimum, a compliance review. The Legal Gray Area of the Initial Grow.
Depending on the allegations, companies must also stay attentive to federal criminal exposure if information is shared with the Drug Enforcement Agency (DEA). The best protective measure a company can take is to conduct its own internal investigation or, at a minimum, a compliance review. The Legal Gray Area of the Initial Grow.
As a result, labs that have received a state license to test either medical or recreational cannabis have historically been denied a DEA Schedule I license to test hemp under the 2018 Farm Bill. This must be repeated per batch analyzed by the lab on an ongoing basis as part of the lab’s QAQC program (internal) and state compliance (external).
Similarly, the North Carolina Department of Agriculture has noted that the “DEA takes the position that synthetically derived THC is illegal as a controlled substance. The Nevada Cannabis Compliance Board recently stated , “products exceeding 0.3% THC, including Delta-8 and Delta-9 THC, would be considered cannabis.
In addition, the Portuguese operation was also granted certification of compliance with GACP and IMC-GAP. Biopharmaceutical Research Company (“BRC”) is a specialty pharmaceutical company that holds several DEA Registrations and is helping pioneer the federally legal cannabis space in the U.S. About Biopharmaceutical Research Company.
Seq (1970) and Drug Enforcement Administration’s (“DEA”) clutches, 2019 hemp production and sales exploded. Steve represents entities, governments and individuals in choosing a structure, preparing and submitting license application, regulation, compliance and litigation, and drafting legislation. Budgeted at $6.1
The CAOA transfers regulation of cannabis from the Drug Enforcement Agency (DEA) to the FDA, the TTB and the Bureau of Alcohol, Tobacco, Firearms & Explosives (ATF) within the Department of Justice—giving the agencies similar regulatory and enforcement authority as they have with alcohol and tobacco.
The firm’s deep expertise in pharmaceutical sciences, FDA regulatory compliance and pharmaceutical product liability litigation and risk management enables it to address complex legal hurdles faced by stakeholders seeking to research, develop, invest in and bring-to-market psychedelic therapies. .”
one of just seven federally DEA- licensed cannabinoid research labs, had some encouraging news about how cannabinoids and cannaflavins can lengthen life spans while improving health spans. Watch Dr. Russo’s Presentation Hunter Land, Ph.D, the VP of Research & Development at Biopharmaceutical Research Company, Inc.,
The cannabis industry might look like just another business for local police, where legal, but the DEA and other federal agencies have a different outlook. Rather there are just too many legal risks and compliance costs, so most financial institutions stay away. The State of Banking.
Department of Agriculture (USDA), not the Drug Enforcement Agency (DEA). Darren has worked on several legal issues in the cannabis space, specializing thus far in industrial hemp, regulatory compliance (hemp and marijuana), and civil and commercial litigation. The 2018 Farm Bill means that hemp will be regulated by the U.S.
Depending on the allegations, companies must also stay attentive to federal criminal exposure if information is shared with the Drug Enforcement Agency (DEA). The best protective measure a company can take is to conduct its own internal investigation or, at a minimum, a compliance review. The Legal Gray Area of the Initial Grow.
For the lab professionals, the Laboratory Compliance Testing Workshop will cover a variety of topics related to cannabis safety testing from sample preparation to regulatory environments. Additionally, Kevin McKernan will share insights into Hop Latent Viroid’s pathology and how that can help breeders produce more resistant plants.
We organize all of the trending information in your field so you don't have to. Join 14,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content